October 14, 2026 · Science & Research Daily Digest
A digest of science, space, biomedicine, and climate research for October 14, 2026, with summaries, links, and commentary.
I. Space and Deep Space
1. Juice uses its Earth flyby to rehearse a Jupiter eclipse and autonomous navigation (Jupiter)
Summary:
On October 14, ESA reviewed Juice's penultimate gravity assist, an Earth flyby on September 28. Since launch on April 14, 2023, the spacecraft has completed three of four planned flybys. This one turned its heading about 20 degrees toward Jupiter; the last Earth flyby is set for 2029, with arrival at Jupiter in 2031. Before closest approach Juice spent about three hours in full umbra and about six hours in partial shadow. It entered the penumbra at 21:30 CEST on September 27; after umbra the batteries were at 54%, above the 35% operating limit, and the arrays resumed generation at 04:14 CEST. All ten science instruments took part, and the EAGLE autonomous-guidance software was exercised with Earth-Moon geometry as a stand-in for a future Jupiter-Io flyby. The two solar arrays total 85 square meters. At Jupiter, sunlight is about 3% as intense as at Earth, and eclipses can last up to five hours.
Links:
Commentary:
The scientific return of the flyby is an in-flight rehearsal of Jovian eclipse operations and moon-limb tracking; the course change is the other result of the same window.
II. Biomedicine
2. Baker lab publishes two Nature papers on proteases designed from scratch (Protein design)
Summary:
Nature published two papers on October 14 from David Baker's group at the University of Washington. The cysteine-protease paper reports enzymes whose folds differ clearly from natural proteases (TM-score below 0.50). Thirteen of 69 designs were active, a 19% success rate, with rate enhancements over the uncatalyzed background of up to about 3×10^7. Six crystal structures match the design models with a C-alpha root-mean-square deviation under 1.2 angstroms, and the enzymes cleave targets inside mammalian cells. The metalloprotease paper uses RFdiffusion to place a zinc active site next to a peptide-binding pocket: 36% of 135 designs cut the intended bond. The best design accelerates hydrolysis by more than 10^8-fold, and four substitutions push that past 10^10-fold. The same approach yields metalloproteases that selectively cut TDP-43, amyloid-beta, and serum amyloid A, with rate enhancements up to about 10^9-fold, and it is used to uncage cytokines and receptor antagonists on cue.
Links:
Commentary:
Cleavage in cells and on disease-linked substrates shows that selectivity can be designed; the papers do not report delivery, immunogenicity, or human efficacy.
3. VS-7375 reports early pancreatic response rates and an FDA-aligned first-line Phase 3 design (Oncology)
Summary:
On October 14, Verastem Oncology released an update from the ongoing Phase 1/2 TARGET-D 101 trial, with an efficacy cutoff of October 7. In the modified intent-to-treat set of metastatic pancreatic ductal adenocarcinoma patients who started VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, at 900 mg once daily on or before July 22, the confirmed objective response rate was 50% (4/8) in second line, 41% (9/22) in second line and later, and 36% (5/14) in third or fourth line. Disease control in the second-line-and-later group was 86%, with landmark six-month progression-free survival of 67% and overall survival of 80%. Sixteen of 22 patients remained on treatment at a median follow-up of 6.4 months. All 12 evaluable patients with detectable mutant circulating tumor DNA at baseline had at least a 50% drop in variant allele frequency by cycle 3 day 1, and seven cleared it below detection at some point. The company said it has aligned with the FDA on a three-arm first-line metastatic pancreatic Phase 3: chemotherapy-free VS-7375 plus anti-EGFR, VS-7375 plus gemcitabine/nab-paclitaxel, and investigator's choice of standard chemotherapy, with progression-free survival and objective response rate as dual primary endpoints, and plans to open the trial by the end of 2026. The adverse-event discontinuation rate on 900 mg monotherapy was 2% (safety cutoff September 29, n=48).
Links:
Commentary:
The 50% confirmed response rate in second line has a denominator of eight and comes from a company release, so the figure can still move with follow-up.
4. Leniolisib Phase II topline data presented at ESID for genetic immune dysregulation (Immunology)
Summary:
On October 14 at the 22nd European Society for Immunodeficiencies meeting in Maastricht (October 14-17), Pharming presented late-breaking Phase II topline results for leniolisib in genetically identifiable primary immunodeficiencies linked to altered PI3K-delta signaling. The single-arm, open-label, intra-patient dose-escalation study enrolled 13 people with variants in CTLA4, SOCS1, NFKB1, or FAS; nine also had common variable immunodeficiency. Treatment lasted 20 weeks, escalating from 10 mg twice daily to 70 mg. Mean spleen volume fell 26.4% (10 of 11 evaluable participants), mean index lymph-node size fell 33.7% (4/4), and percent predicted DLCO rose by a mean of 8.0% among seven participants with impaired gas exchange at baseline. All 12 participants who completed the study entered the three-year extension NCT06990529. The company said treatment-related adverse events were Grade 1 and that no new safety signals were identified. The indication is not approved.
Links:
Commentary:
Spleen-volume reductions showed up in nearly every evaluable participant, but there is no control arm, and the lymph-node and liver denominators are smaller still.
5. FDA clears an IDE for Cadence's biomarker-guided stimulation study in focal drug-resistant epilepsy (Neuromodulation)
Summary:
On October 14, Cadence Neuroscience said the U.S. FDA approved an investigational device exemption so the prospective, multicenter BTSEE study can begin. The study plans to evaluate biomarker-targeted stimulation in 45 children and adults with focal drug-resistant epilepsy at up to 10 U.S. comprehensive epilepsy centers (NCT06424977), aiming to support a future humanitarian device exemption. The company says the system uses patient-specific neural biomarkers to guide stimulation and measure the response. The 89% responder rate and the figure of about 40% of patients free of disabling seizures for at least 12 months, cited in the release, come from a 2019 retrospective analysis of 21 patients treated with chronic subthreshold cortical stimulation, not from this prospective study. The device is not FDA approved or cleared.
Links:
Commentary:
The IDE opens enrollment for a 45-person prospective study; the 2019 retrospective numbers are not evidence that the new system already works.
6. Walvax holds the Phase I start-up meeting for a lyophilized shingles mRNA vaccine (Vaccines)
Summary:
Securities Times and Yicai reported on October 14 that Walvax Biotechnology's announcement 2026-083 said subsidiaries Beijing Walvax Innovation, Yunnan Vaccine Laboratory, and Yuxi Walvax, together with Fudan University and Shanghai RNACure, held the Phase I start-up meeting that day for a lyophilized varicella-zoster mRNA vaccine. The filing classifies it as a prophylactic biological product category 1.2. Phase I is a randomized, blinded, controlled study of safety in healthy people aged 40 and older, intended to prevent shingles. The company said approved shingles vaccines elsewhere use live-attenuated or recombinant-protein platforms, and that no mRNA product in this class is yet approved. The announcement does not give enrollment size, site lists, or immunogenicity data.
Links:
- Securities Times — Walvax starts Phase I for a lyophilized shingles mRNA vaccine
- Yicai — Walvax lyophilized shingles mRNA vaccine Phase I start
Commentary:
What happened today is a start-up meeting and a public description of the trial design, not a safety readout after the first doses.
7. MassNet releases 1.5 billion spectra and a de novo sequencing model (Proteomics)
Summary:
Nature Methods published the open-access MassNet paper on October 14. The corpus holds 1.5 billion tandem spectra from high-quality data-dependent acquisition runs across 35 species, including about 1.7 million peptide precursors from human samples, stored in a compact MSDT tensor format. XuanjiNovo, a non-autoregressive transformer trained with curriculum learning for de novo peptide sequencing, improves 38.35% to 143.57% over previous state-of-the-art methods on human Astral data. The paper says the same resource also supports retention-time prediction and peptide-spectrum match rescoring. The main text adds that the spectra come from 648 projects in PRIDE and iProX and about 30 terabytes of raw data, yielding 548 million target peptide-spectrum matches after the searches were combined.
Links:
Commentary:
The gain is a relative improvement on a sequencing benchmark, not a clinical assay or a drug-target validation.
III. Climate and Environment
8. BioScience publishes the 2026 state-of-the-climate report: 7 of 16 indicators at record extremes (Climate)
Summary:
On October 14, Oregon State University announced that the seventh annual report led by William Ripple, Christopher Wolf, and colleagues was published that day in BioScience. Of 16 planetary vital signs, seven are at record extremes. Atmospheric carbon dioxide is at 428 ppm, higher than at any time in the past 2 million years and about 50% above the pre-industrial level. The reported warming rate rose from about 0.19°C per decade in 1970-2010 to about 0.36°C per decade since. Fossil-fuel consumption rose 0.9% in 2025, with oil, coal, and gas each at record highs, and annual energy-related carbon dioxide emissions passed 41 billion tonnes for the first time. Glacier thickness and Greenland ice mass are at recorded lows. AGU's Eos added the same day that global sea level, ocean heat content, and the concentrations of the three main greenhouse gases are also at record extremes, and that renewable generation surpassed coal in 2025. Wolf said low-carbon sources now provide about 43% of global electricity, while fossil-fuel use and emissions remain at record levels. The authors expect a very strong El Niño this fall.
Links:
Commentary:
A rising share of low-carbon electricity and still-rising fossil-fuel consumption and emissions sit side by side in the same annual report.
9. Probabilistic bias correction pushes skill further on the two-to-six-week forecast (Forecasting)
Summary:
MIT News and The Verge reported on October 14 that a probabilistic bias correction (PBC) paper from Microsoft Research, MIT, ECMWF, and collaborators appeared the same day in Nature. The method does not replace the underlying model. It learns to correct systematic errors in historical probabilistic forecasts, runs on ordinary CPUs, and is open source. The paper abstract says PBC about doubles the subseasonal skill of ECMWF's AI forecasting system and improves an operationally debiased dynamical model for 91% of pressure, 92% of temperature, and 98% of precipitation targets. In ECMWF's 2025 real-time forecasting competition, the associated global forecasts placed first for every weather variable and lead time. MIT's Judah Cohen said the approach was the first to beat climatological averages consistently at two to six weeks and that the gain for extremes was statistically significant. The Verge reported that Rhiza Research is testing methods including PBC with the Kenya Meteorological Service Authority, with Gates Foundation funding, ahead of an expected stronger El Niño rainy season.
Links:
Commentary:
This is a post-processing layer on models that already exist; ECMWF's machine-learning lead also noted that putting it into an operational pipeline is the harder step.
10. Cornell finds more beneficial insects at two sheep per hectare on a solar farm, and fewer honey bees at eight (Agrivoltaics)
Summary:
On October 14, Cornell University described two grazing studies. A College of Agriculture and Life Sciences team spent three years varying stocking rates with the university's teaching flock at the Cascadilla Community Solar Farm in Dryden, New York. Compared with a mowed control, two sheep per hectare raised the combined abundance of wild bees, honey bees, and lady beetles by 38%, driven mainly by an 83% increase in honey bees. At four sheep per hectare, beneficial-insect abundance was similar to the control while vegetation control was better. At eight per hectare, vegetation control was strongest and flock health stayed high, but honey-bee abundance fell 45%. The insect results are in an Environmental Research Letters paper published October 7, with Leana Zoller as first author and Steve Grodsky as senior author. A business-school team described a spreadsheet decision tool in Manufacturing & Service Operations Management on September 28; United Agrivoltaics has added it to onboarding.
Links:
Commentary:
The stocking rate that controls grass best is not the rate that supports honey bees best, so a grazing contract has to say which goal it is buying.
IV. Basic Research
11. Wave coarsening in a non-reciprocal metamaterial spontaneously forms a time crystal (Physics)
Summary:
Nature published a paper on October 14 from groups including Amsterdam, Birmingham, Delft, Leiden, and Cambridge, with authors Jonas Veenstra, Jack Binysh, and Corentin Coulais. In an active elastic metamaterial they observe wave coarsening: vibrations spontaneously grow in wavelength, period, and amplitude until a globally synchronized time crystal forms, without an external beat. The necessary ingredient is non-reciprocal interaction between components. The University of Birmingham said a two-dimensional honeycomb of 37 active units self-oscillated at about 30 hertz past a stability threshold, after which longer waves dominated, and that an elastic ring of 24 motorized units settled from high-frequency deformations into a slow collective cycle. Random disturbances did not destroy the order. The experimental material embeds more than 100 sensors and actuators. Breaking momentum conservation arrests the coarsening and reveals a far-from-equilibrium analogue of chiral topological edge modes.
Links:
- Nature — Wave coarsening drives time crystallization in mechatronic metamaterials
- University of Birmingham — Vibrating material organises itself into a single rhythm
Commentary:
The synchrony comes from non-reciprocal coupling among the parts, not a beat issued by a central controller; robotic uses remain the authors' stated next step.
12. Stimulating about 20 motor-cortex neurons triggers a learned movement in mice (Neuroscience)
Summary:
Nature published a University of California San Diego paper on October 14, led by Qiyu Chen with senior author Takaki Komiyama and based on work begun by An Wu, who died in 2023. As mice learn a lever press, layer 2/3 of primary motor cortex develops a reproducible spatiotemporal activity pattern. Using two-photon calcium imaging to read activity and holographic optogenetics to write it, the team found that brief synchronous activation of about 20 neurons whose activity starts before a voluntary movement induced movements resembling the learned one, and recruited similar learned activity in neurons that were not directly stimulated. Neurons whose activity followed movement onset did not. Success depended on the motor cortex state just before stimulation and on whether the mouse was still engaged in the task. Some trials produced the learned activity without a visible movement, so the pattern is not only a passive echo of motion. Komiyama noted that a mouse brain has about 70 million neurons.
Links:
- Nature — Targeted stimulation of motor cortex ensembles drives learned movements
- UC San Diego — Activating about 20 brain cells
Commentary:
The causal evidence is from mouse cortex during a trained task; using that logic to restore specific daily movements in people is still a circuit problem and a clinical problem.
Today's Summary
- Juice's September 28 Earth flyby rehearsed a Jupiter eclipse: batteries were still at 54% after about three hours in full shadow, with all ten instruments and the EAGLE navigation software in the campaign.
- Nature the same day reported designable cysteine and zinc proteases, and a mouse result in which about 20 early-onset neurons triggered a learned movement; MassNet released 1.5 billion mass spectra.
- The confirmed pancreatic response rates for VS-7375 come from a small company update, leniolisib is a 13-person single-arm topline, Cadence received an IDE for 45 people, and Walvax only held the Phase I start-up meeting for its shingles mRNA vaccine.
- The climate report put 7 of 16 vital signs at record extremes while fossil-fuel use was still rising; PBC is a correction layer that sits on top of existing two-to-six-week forecast models.
Daily Framing:
October 14 was a rewrite day: proteases, movement-onset neurons, and two-to-six-week forecast errors were all treated as things that can be designed or corrected, while the climate report showed the power transition has not yet pulled emissions off their records.
This digest is compiled from real-time search results and is for reference only.